Elamipretide is a short peptide that is able to cross mitochondrial membranes and reach the inner mitochondrial membrane. It basically interacts with the cardiolipin, which is a component of the inner mitochondrial membrane. And it was tested as a molecule in different models and elamipretide was able to improve mitochondrial function in different levels. That’s why from the bench elamipretide was also tested in humans and there were already Phase I, Phase II and Phase III clinical trials recently published And what it looks is that elamipretide seems to work on PMM on primary mitochondrial myopathy patients of nuclear origin...
Elamipretide is a short peptide that is able to cross mitochondrial membranes and reach the inner mitochondrial membrane. It basically interacts with the cardiolipin, which is a component of the inner mitochondrial membrane. And it was tested as a molecule in different models and elamipretide was able to improve mitochondrial function in different levels. That’s why from the bench elamipretide was also tested in humans and there were already Phase I, Phase II and Phase III clinical trials recently published And what it looks is that elamipretide seems to work on PMM on primary mitochondrial myopathy patients of nuclear origin. And this was confirmed in a recent trial that was published 18 months ago now, but post-hoc analysis is more recent. And mainly patients with nuclear DNA calls of PMM, of mitochondrial myopathy, responded quite well in terms of meters they were walking more at the six-minute walk test. So elamipretide is an interesting molecule because it can do something for our patients with mitochondrial myopathy of nuclear origin. We are now waiting for the results of a new study called NuPOWER that was closed recently and we are looking forward to see what happened to these patients under elamipretide.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
